StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Each factor shows TRAW's percentile within the scored universe — observational ranking, not a recommendation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $2.22 | $2.02 | -9.01% | 25.9M |
| 05-12 | $1.98 | $1.68 | -15.15% | 2.7M |
| 05-13 | $1.61 | $1.72 | +6.83% | 1.3M |
| 05-14 | $1.69 | $1.63 | -3.55% | 0.9M |
| 05-15 | $1.55 | $1.88 | +21.29% | 1.9M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2026 (Est.) Expected 2026-08-12 | Q3 2024 2024-09-30 | Q3 2023 2023-09-30 |
|---|---|---|---|
Revenue | $0.00 | $170.00K | $170.00K |
Operating Income | Not available | $-137.10M | $-15.84M |
Net Income | Not available | $-136.60M | $-14.76M |
EPS (Diluted) | $-0.79 | $-31.86 | $-17.59 |
Total Assets | Not available | $8.94M | $27.04M |
Total Liabilities | Not available | $10.97M | $12.52M |
Cash & Equivalents | Not available | $5.41M | $25.24M |
Free Cash Flow OCF − CapEx | Not available | $-29.40M | $-13.52M |
Shares Outstanding | Not available | 3.03M | 21.00M |
No sell-side coverage available for TRAW.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.